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Background: Early graft thrombosis and bleeding complications remain important causes of early graft loss
following kidney transplantation in patients with antiphospholipid syndrome. Anti-β2-glycoprotein I IgG is a
disease-specific antibody in patients with antiphospholipid syndrome. Although plasmapheresis is partially effective
for antibody removal, the optimal treatment allowing successful transplantation in patients with antiphospholipid
syndrome has not been established. This is the first report of a patient with antiphospholipid syndrome who
successfully underwent living-donor kidney transplantation following prophylactic plasmapheresis for removal of
anti-β2-glycoprotein I IgG.
Case presentation: A 37-year-old Japanese female was scheduled to undergo a living-donor kidney transplant
from her mother. At age 25 years, she experienced renal vein thrombosis, was diagnosed with antiphospholipid
syndrome secondary to systemic lupus erythematosus, and was subsequently treated with prednisolone and
warfarin. At age 37 years, she was diagnosed with end stage kidney disease, requiring maintenance hemodialysis
because of recurrent renal vein thrombosis despite taking anticoagulation therapy. The pretreatment protocol
consisted of prophylactic plasmapheresis plus full anticoagulation therapy to counteract the risks of early graft
thrombosis. Anticardiolipin and anti-β2-glycoprotein I IgGs were successfully removed by both double filtration
plasmapheresis and plasma exchange. The allograft kidney began to function soon after transplantation. No obvious
thrombotic complications were observed after transplantation, although anti-β2-glycoprotein I IgG increased to the
level observed before plasmapheresis. One year after transplantation, the patient’s kidney function remains stable
while receiving anticoagulation therapy as well as a maintenance immunosuppressive regimen.
Conclusion: Prophylactic plasmapheresis plus full anticoagulation therapy may be an effective strategy in patients
with antiphospholipid syndrome undergoing living-donor kidney transplantation.
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Early graft thrombosis and bleeding complications remain
important causes of early graft loss following kidney trans-
plantation in patients with antiphospholipid syndrome
(APS) [1-4]. APS is a multisystem autoimmune disorder
characterized clinically by recurrent arterial and/or venous
thrombosis and/or pregnancy morbidity, and serologically* Correspondence: sofue@med.kagawa-u.ac.jp
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cluding lupus anticoagulant (LA), anticardiolipin (aCL)
and anti-β2-glycoprotein I (anti-β2GPI) antibodies. APS
can be classified as primary or secondary to systemic lupus
erythematosus (SLE). aCL antibody has been regarded as a
major antiphospholipid antibody and a marker for APS. In
contrast, anti-β2GPI antibody is a relatively new disease-
specific antibody for APS and considered a cause of throm-
botic complications [5,6].
The “two hit” model of thrombosis in APS patients
states that an initiating “first hit” injury disrupts thetd. This is an Open Access article distributed under the terms of the Creative
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tion as a “second hit” [7]. The “first hit” injury to the
endothelium can include trauma, surgery, infection and
drugs [8,9], making surgical procedures an important
risk factor for thrombosis in patients with APS.
Anticoagulation therapy with warfarin is recommended
in patients with APS to prevent recurrent arterial and/or
venous thrombosis [10,11]. Anticoagulation therapy before
and at the time of kidney transplantation has been re-
ported to reduce the risk of early posttransplant throm-
bosis in the allograft [2]. However, anticoagulation therapy
increases the risk of bleeding complications, which may
lead to early allograft loss [3]. Moreover, patients with
APS are at high risk of allograft thrombosis even when
taking anticoagulation therapy [3].
Prophylactic temporary plasmapheresis for antibody
removal has been reported effective in patients with APS
and acute thrombotic complications [12,13]. Plasma-
pheresis has been found to reduce serum titers of aCL
and anti-β2GPI IgGs [12,14]. Although anticoagulation
therapy with heparin is recommended for pregnant
women with APS [15], prophylactic plasmapheresis has
been reported partially effective in these women [16,17].
To our knowledge, prophylactic plasmapheresis has been
reported useful in only one patient with primary APS
undergoing kidney transplantation [4]. Therefore, the
optimal treatment strategy allowing successful kidney
transplantation in patients with APS has not yet been
established. This report describes a patient with second-
ary APS, who underwent prophylaxis with plasmapher-
esis, in addition to full anticoagulation therapy, prior to
successful living-donor kidney transplantation.
Case presentation
A 37-year-old Japanese woman, scheduled to undergo a
living-donor, ABO-compatible kidney transplant from
her mother, was referred to our kidney transplant center
in July 2012. At age 25 years, she had experienced acute
kidney injury (AKI) due to bilateral renal vein throm-
bosis. At that time, she was diagnosed with APS second-
ary to SLE because of the repeated detection of high
titers of antibody to double-stranded DNA (300 U/ml)
and aCL IgG (39.6 U/ml) and low serum complement 3
(C3; 34 mg/dl) and complement 4 (C4; 2 mg/dl) concen-
trations. Following the diagnosis of AKI, she underwent
hemodialysis (HD) for 2 weeks. Plasma exchange (PE),
methylprednisolone pulse therapy and anticoagulation
therapy ameliorated her AKI, and she no longer needed
HD. She subsequently received immunosuppressive ther-
apy with 5 mg prednisolone and anti-coagulant therapy
with warfarin, to maintain an international normalized
ratio (INR) between 2.0 and 3.0. During this time, her
serum creatinine concentration remained stable (1.2 to
1.4 mg/dl; 103 to 120 μmol/L). However, at age 36 years,she experienced recurrent bilateral renal vein thrombosis
and was again diagnosed with AKI. At the time of recur-
rent thrombosis, her INR was 1.5, which was lower than
the target therapeutic range, despite receiving a sufficient
amount of warfarin (3.0 mg/day). At the time of recur-
rence, her LA was positive (ratio 1.3; normal range <1.3),
as determined by the Gradipore-LA Dilute Russell’s viper
venom time (dRVVT) test (Medical & Biological Labora-
tories Co., Ltd., Nagoya, Japan). The combination of im-
munosuppressive and anticoagulant therapy could not
restore her kidney function. At age 37 years, she was
diagnosed with end stage kidney disease, requiring main-
tenance HD. Because of thrombosis, three consecutive
operations for arteriovenous fistula failed. Finally, an ar-
teriovenous graft was created as vascular access for HD.
All tests performed to investigate the causes of thrombo-
philia were within normal ranges, except for aPL assays.
SLE activity was considered low because her serum C3
(91 mg/dl) and C4 (23 mg/dl) concentrations were nor-
mal, and there was no evidence of antibody to double-
stranded DNA (<5.0 IU/ml). Her pre-treatment aCL and
anti-β2GPI IgG concentrations were 42.6 U/ml (normal
range <10 U/ml) and 13.9 U/ml (normal range <3.5 U/ml),
respectively. Plasma aCL IgG (MESACUP cardiolipin test,
Medical & Biological Laboratories Co., Ltd) and anti-
β2GPI IgG (anti-CL-β2GPI EIA kit, Yamasa Co., Choshi,
Japan) were measured by enzyme-linked immunosorb-
ent assays. The dRVVT test before kidney transplant-
ation was positive (ratio 1.3). Her 63-year-old mother
had sufficient eGFR (109 ml/min/1.73 m2) and two
human leukocyte antigen (HLA) mismatches with
the recipient. Tests for histocompatibility, including
complement-dependent cytotoxicity (CDC) crossmatch,
flow crossmatch and flow cytometry panel-reactive anti-
body (PRA) tests, showed that the donor and recipient
were histocompatible.
Kidney transplantation was planned for February 2013.
The pretreatment protocol consisted of prophylactic
plasmapheresis plus full anticoagulation therapy to coun-
teract the risks of early graft thrombosis and bleeding.
Double filtration plasmapheresis (DFPP) was performed
using a KM-8900EX (Kuraray Medical, Tokyo, Japan) ma-
chine with a Plasmacure PE-05 plasma separator (Kuraray
Medical) and Evaflux 2A20 plasma fractionator (Kawasumi
Laboratories, Tokyo, Japan). During DFPP, 2500 ml of
blood was treated, with replacement by 450 ml of 11.25%
albumin solution. PE was performed using a KM-8900EX
machine with a Plasmacure PE-05 plasma separator, with
replacement by 2700 ml of fresh frozen plasma (FFP).
The clinical course and treatment of the patient are
shown in Figure 1. The induction immunosuppressive
regimen consisted of combination therapy with prolonged-
release tacrolimus, mycophenolate mofetil (MMF), methyl-
prednisolone and basiliximab. MMF (1000 mg/day), was
Figure 1 Clinical course and treatment of the patient. Abbreviations: PSL, prednisolone; mPSL, methylprednisolone; MMF, mycophenolate
mofetil; S-Cr, serum creatinine; DFPP, double filtration plasmapheresis; PE, plasma exchange; aCL, anticardiolipin; IgG, immunoglobulin G; aβ2GPI,
anti-β2 glycoprotein I.
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tion therapy with 2.5 mg/day warfarin was replaced by daily
continuous injections of heparin (10,000 units/day), starting
7 days before transplantation, with the dose of heparin ad-
justed to maintain an activated partial thromboplastin time
(APTT) of 40 to 60, with heparin suspended 3 hours before
surgery. DFPP was performed on days −6 and −4 and PE
on day −1. aCL and anti-β2GPI IgGs were successfully re-
moved by both DFPP and PE, with both being within
normal range on day −1 (3.8 IU/ml and 1.9 U/ml, re-
spectively). No apparent adverse effects were observed
during plasmapheresis.
The right kidney of the donor was transplanted into
the right iliac fossa of the recipient. Intraoperative bleed-
ing was 582 ml and the amount of transfused red cell
concentrates was 560 ml. Post-operative hemoglobin
was 9.4 g/dl. Allograft kidney function rapidly appeared
after kidney transplantation. Anti-coagulation therapy with
heparin (10,000 units/day) was restarted on the morning of
day +1 and replaced by warfarin on day +14. After trans-
plantation, aCL and anti-β2GPI IgGs increased to their
levels before plasmapheresis. However, no obvious throm-
botic complications, including increased serum d-dimer
levels, were observed after transplantation. The patient
was discharged 21 days after transplantation, receivingmaintenance anti-coagulation therapy with warfarin (3 mg/
day) and a maintenance immunosuppressive regimen, con-
sisting of prolonged-release tacrolimus (6 mg/day), MMF
(1500 mg/day) and methylprednisolone (4 mg/day).
Three months after kidney transplantation, her serum
creatinine level was stable (0.69 mg/dl; 59.5 μmol/L) with-
out apparent proteinuria, and her titer of anti-β2GPI IgG
was high (17.8 U/ml). Pathological findings of a protocol
allograft biopsy taken 3 months after kidney transplant-
ation are shown in Figure 2. There was no evidence of
arteriole thrombosis or lupus nephritis. Her Banff score
was t1 i1 g0 v0 ci0 ct1 mm0 cv0 ah0 ptc0; and immuno-
fluorescence findings were negative. Borderline changes
were diagnosed.
At the present time, one year after transplantation, her
serum creatinine concentration remains stable (0.67 mg/dl;
57.8 μmol/L), although she has a high anti-β2GPI IgG titer
(31.9 U/ml) and is positive on the dRVVT test (ratio 1.3).
She has not experienced any bleeding or thrombotic com-
plications while remaining on anticoagulant therapy with
warfarin to maintain an INR between 2.0 and 3.0.
Discussion
We have shown here that prophylaxis with plasmapher-
esis and full anticoagulation therapy was an effective
A B
C
Figure 2 Renal histopathological findings showing the absence of (A) arteriole thrombosis (hematoxylin and eosin staining, low power
field) and (B) lupus nephritis (periodic acid-Schiff staining, high power field), but (C) slight lymphocyte infiltration into tubules (Banff
score, t1) (hematoxylin and eosin staining, high power field).
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living-donor kidney transplantation. These treatments are
important because once the thrombotic process is initi-
ated, there is no effective therapy available to lyse the clot
and to recover the allograft [3].
Prophylactic plasmapheresis could reduce both aCL
and anti-β2GPI IgGs to their normal ranges. Although
we found that DFFP removed 70% of both aCL and anti-
β2GPI IgGs, a previous report found that DFPP with
Evaflux 2A20 removed around 20% of total IgG [18]. We
also found that PE removed 56% of both aCL and anti-
β2GPI IgGs, whereas product information for Plasma-
cure PE-05 stated that PE removed 96% of total IgG
[19]. Treatment with PE has been reported to reduce
anti-HLA antibodies while not affecting tetanus IgG in
kidney transplant recipients [20]. As replacement with
FFP should be effective in maintaining permanent im-
munity, we considered that our method of plasmapheresis
could remove disease-specific IgG while leaving perman-
ent immunity intact. Unfortunately, however, we could
not determine whether plasmapheresis affected the results
of dRVVT tests. A case report showed that treatment with
plasmapheresis decreased dRVVT test results [21]. Thus,
IgG removal by plasmapheresis would remove LA as well
as other aPLs.
We used prophylactic temporary plasmapheresis in
this patient only to prevent perioperative thrombotic
complications. Endothelial injuries can result from thesurgical procedures used during kidney transplantation,
including perfusion with organ preservation solution and
ischemia/reperfusion injury, although these injuries are
considered temporary. Therefore, temporary prophylactic
aPL removal may have reduced the risk of thrombosis dur-
ing the early post-operative period. Moreover, perioperative
bleeding complications may be prevented by discontinuing
anticoagulant therapy. That is, removal by plasmapheresis
of a sufficient amount of anti-β2GPI IgG could allow anti-
coagulant therapy to be safely discontinued for 24 hours
perioperatively. Although the maintenance immunosup-
pressive regimen could not reduce anti-β2GPI IgG after
kidney transplantation, continuous plasmapheresis to re-
move increased anti-β2GPI IgG was not recommended.
An international consensus statement has suggested that
plasmapheresis be used only at the time of thrombotic
complications [10]. Sufficient anticoagulation therapy dur-
ing the maintenance phase after kidney transplantation is
considered effective in preventing thrombotic complica-
tions in patients with APS.
A recent non-randomized pilot study showed that ri-
tuximab, a chimeric monoclonal antibody against CD20,
may play a role in the treatment of patients with refrac-
tory catastrophic APS [22]. In Japan, rituximab is fre-
quently used as an induction immunosuppressant for
ABO-incompatible kidney transplantation [23]. However,
treatment with rituximab was unable to change aPL pro-
files [24]. Moreover, two randomized clinical trials with
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did not show rituximab efficacy in patients with SLE, did
not include patients with APS [25,26]. Because we con-
sidered the efficacy and safety of rituximab in patients
with APS secondary to SLE not established, we did not
treat our patient with rituximab prophylaxis.
The long-term prognosis of patients with APS after kid-
ney transplantation has been reported to be poor [27]. Al-
though these patients did not develop major thrombotic
complications, the presence of aCL IgG was associated
with poor transplantation outcomes [27]. Recently, anti-
β2GPI IgG was reported to initiate arteriosclerotic changes
[6]. Long-term monitoring of cardiovascular disease and
kidney function is necessary for these patients.
Conclusions
We describe here the successful living-donor kidney trans-
plantation in a patient with secondary APS following a
combination of prophylactic plasmapheresis and anticoa-
gulation therapy. Although it is impossible to conclude
that plasmapheresis is useful as prophylaxis for throm-
bosis in patients with APS undergoing kidney transplant-
ation based on the findings in a single patient, our results
suggest that further studies are warranted.
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